Literature DB >> 22969978

Competing causes of death in patients with oropharyngeal cancer treated with radiotherapy.

Johnny Kao1, K H Vincent Lau, Charles C L Tong, Chien-Ting Chen.   

Abstract

Radiation with or without chemotherapy is considered the mainstay of treatment for the majority of patients with oropharyngeal cancer. The goal of this study was to analyze competing causes of mortality in patients with oropharyngeal cancer with long-term follow-up. We queried the Surveillance, Epidemiology and End Results (SEER) database and identified 3728 patients with oropharyngeal cancer treated between 1988 and 2001 with definitive radiotherapy. We analyzed predictors of overall survival and risks of mortality from index oropharyngeal cancer, second primary cancer, cardiovascular disease and other causes using a cumulative incidence analysis and Cox multivariate analysis. With a median follow-up of 6.8 years, the 5- and 10-year overall survival was 37 and 22%, respectively. At 5 years, the risk of mortality from primary oropharyngeal cancer was 35%. Between years 3 and 10, 69% of mortalities were attributed to causes other than the index cancer. Despite advances in the non-surgical treatment of oropharyngeal cancer, patients remain at significant risk of cancer- and non-cancer-related mortality.

Entities:  

Year:  2012        PMID: 22969978      PMCID: PMC3438677          DOI: 10.3892/etm.2012.494

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  27 in total

Review 1.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee.

Authors:  Thomas A Pearson; Steven N Blair; Stephen R Daniels; Robert H Eckel; Joan M Fair; Stephen P Fortmann; Barry A Franklin; Larry B Goldstein; Philip Greenland; Scott M Grundy; Yuling Hong; Nancy Houston Miller; Ronald M Lauer; Ira S Ockene; Ralph L Sacco; James F Sallis; Sidney C Smith; Neil J Stone; Kathryn A Taubert
Journal:  Circulation       Date:  2002-07-16       Impact factor: 29.690

2.  Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years.

Authors:  Caroline H Shiboski; Brian L Schmidt; Richard C K Jordan
Journal:  Cancer       Date:  2005-05-01       Impact factor: 6.860

3.  High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma.

Authors:  Lisa Licitra; Federica Perrone; Paolo Bossi; Simona Suardi; Luigi Mariani; Raffaella Artusi; Maria Oggionni; Chiara Rossini; Giulio Cantù; Massimo Squadrelli; Pasquale Quattrone; Laura D Locati; Cristiana Bergamini; Patrizia Olmi; Marco A Pierotti; Silvana Pilotti
Journal:  J Clin Oncol       Date:  2006-12-20       Impact factor: 44.544

4.  Recent advances in head and neck cancer.

Authors:  Robert I Haddad; Dong M Shin
Journal:  N Engl J Med       Date:  2008-09-11       Impact factor: 91.245

Review 5.  Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma.

Authors:  J Kao; A T Sikora; S Fu
Journal:  Curr Cancer Drug Targets       Date:  2009-12       Impact factor: 3.428

Review 6.  Treatment considerations for head and neck cancer in the elderly.

Authors:  Eric M Genden; Alessandra Rinaldo; Ashok R Shaha; Gary L Clayman; Jochen A Werner; Carlos Suárez; Alfio Ferlito
Journal:  J Laryngol Otol       Date:  2005-03       Impact factor: 1.469

7.  Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.

Authors:  A S Garden; J Harris; E E Vokes; A A Forastiere; J A Ridge; C Jones; E M Horwitz; B S Glisson; L Nabell; J S Cooper; W Demas; E Gore
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

8.  Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma.

Authors:  Sonia A Duffy; David L Ronis; Scott McLean; Karen E Fowler; Stephen B Gruber; Gregory T Wolf; Jeffrey E Terrell
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

9.  Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma.

Authors:  Amir Lavaf; Eric M Genden; Jamie A Cesaretti; Stuart Packer; Johnny Kao
Journal:  Cancer       Date:  2008-02-01       Impact factor: 6.860

10.  Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.

Authors:  J K Salama; K M Stenson; E O Kistner; B B Mittal; A Argiris; M E Witt; F Rosen; B E Brockstein; E E W Cohen; D J Haraf; E E Vokes
Journal:  Ann Oncol       Date:  2008-06-06       Impact factor: 32.976

View more
  1 in total

1.  Cause-specific mortality in HPV+ and HPV- oropharyngeal cancer patients: insights from a population-based cohort.

Authors:  Cecilie Nørregaard; Christian Grønhøj; David Jensen; Jeppe Friborg; Elo Andersen; Christian von Buchwald
Journal:  Cancer Med       Date:  2017-11-24       Impact factor: 4.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.